Table 1.

Independent factors for survival prediction multivariate analysis of patients

Variables	Characteristics	Univariate	P value	Multivariate	P value
		HR (95% CI)		HR (95% CI)
SRCC status	Non-SRCC vs. Con-SRCC	1.16 (0.99–1.36)	0.06	1.16 (0.99–1.36)	0.06
	Non-SRCC vs. SRCC	1.48 (1.25–1.75)	<0.001	1.45 (1.22 –1.71)	<0.001
Age (years)	<60 vs. ≥60	1.17 (1.02–1.34)	0.021
Gender	Male vs. Female	0.98 (0.84–1.13)	0.74
Tumor size (cm)	<5 vs. ≥5	2.62 (2.26–3.03)	<0.001	1.49 (1.27–1.75)	<0.001
Tumor location	Non-AEG vs. AEG	1.21 (1.04–1.40)	0.012
Tumor grade	G1–2 vs. G3-4	1.61 (1.34–1.94)	<0.001
Residual degree	R0 vs. R1/R2	2.98 (2.52–3.54)	<0.001	1.41 (1.17–1.71)	<0.001
T stage	T1–3 vs. T4	3.27 (2.77–3.86)	<0.001
N stage	N0 vs. N1-3	3.43 (2.84–4.14)	<0.001
M stage	M0 vs. M1	3.67 (3.09–4.36)	<0.001
TNM stage	I vs. II	2.00 (1.48–2.70)	<0.001	1.88 (1.38–2.55)	<0.001
	I vs. III	5.08 (3.93–6.55)	<0.001	3.88 (2.96–5.10)	<0.001
	I vs. IV	11.64 (8.74–15.51)	<0.001	7.58 (5.50 –10.42)	<0.001
Nervous invasion	Negative vs. Positive	1.62 (1.30–2.02)	<0.001
Capillary invasion	Negative vs. Positive	1.62 (1.39–1.88)	<0.001	1.20 (1.03–1.41)	0.019
Extranodal metastasis	Negative vs. Positive	2.50 (2.11–2.95)	<0.001	1.28 (1.07–1.52)	0.007
Chemotherapy	With vs. Without	1.25 (1.09-1.43)	0.002	1.46 (1.27–1.68)	<0.001

P value and ORs were estimated by the Cox regression model

HR Hazard ratio, 95% CI 95% confidence interval of the risk ratio, non-SRCC cancers without signet-ring cells, con-SRCC cancers with <50% presence of signet-ring cells, SRCC cancers with >50% presence of signet-ring cells, U upper, M middle, L lower, AEG adenocarcinomas of the esophagogastric junction